IVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets

IVI will complete the technology transfer by 2025

2024-03-20

(Press-News.org) IVI will complete the technology transfer by 2025 Oral Cholera Vaccine to be manufactured by Biological E. Limited for India and international markets

March 20, 2024, SEOUL, Republic of Korea and HYDERABAD, India — The International Vaccine Institute (IVI), an international organization with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health, today announced that it has commenced a technology transfer of simplified Oral Cholera Vaccine (OCV-S) to Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company.

Following the signing of a technology license agreement in November last year, IVI has begun providing the technical information, know-how, and materials to produce OCV-S at BE facilities and will continue to support necessary clinical development and regulatory approvals. IVI and BE entered this partnership during an unprecedented surge of cholera outbreaks worldwide and aim to increase the volume of low-cost cholera vaccine in India as well as the global public market.

IVI will complete the technology transfer by 2025 and the oral cholera vaccine will be manufactured for India and international markets by Biological E. Limited.

Dr. Jerome Kim, Director General of IVI, said: “In an era of heightened risk of poverty-associated infectious diseases such as cholera, the world needs a sustainable source of high-quality, affordable vaccines and committed manufacturers to supply them. We are pleased to partner with Biological E., a company with a proven history of making life-saving vaccines accessible globally, to address this supply gap and protect communities from this deadly, though preventable, disease.”

Ms. Mahima Datla, Managing Director, Biological E. Limited, said: “We are glad to be in collaboration with IVI for the manufacture of simplified Oral Cholera Vaccine. Our efforts are aimed to not only combat the disease but to also be part of a sustained legacy of innovation, collaboration, and health stewardship. Together with IVI, we are happy to be shaping a healthier and more resilient future by making this vaccine accessible globally.”

This technology transfer and licensing agreement is the sixth of its kind for IVI, transferring such technology to manufacturers in India, the Republic of Korea, Bangladesh, and South Africa. All these partnerships have led to or seek to achieve, pre-qualification (PQ) from the World Health Organization, a designation that enables global agencies such as UNICEF to procure the vaccine for the global market. BE already has 9 vaccines with WHO PQ in its portfolio, and IVI and BE will pursue WHO PQ for OCV-S as well, following national licensure in India.

Dr. Julia Lynch, Director of IVI’s Cholera Program, said: “The cholera situation is dire, and the availability and use of oral cholera vaccine is an essential part of a multifaceted approach to cholera control and prevention, especially as outbreaks increase and the global vaccine supply remains strained. With more manufacturers like BE entering the market, the future supply situation looks strong. IVI remains committed to ensuring the availability of the oral cholera vaccine and to developing new and improved vaccines that are equally safe, effective, and affordable and made around the world, for the world.”

OCV-S is a simplified formulation of OCV with the potential to lower production costs while increasing production capacity for current and aspiring OCV manufacturers. IVI’s development of OCV-S and ongoing technology transfers are part of an institutional strategy to confront cholera with 3 main goals: 1) Ensure supply of OCV 2) Improve cholera vaccines 3) Support OCV use and introduction. The Bill & Melinda Gates Foundation has been supporting IVI’s cholera program since 2000 and is funding this latest technology transfer to BE.

###

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health.

IVI’s current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world’s first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024.

IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 39 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, and Thailand provide state funding. For more information, please visit https://www.ivi.int.

About Biological E. Limited

Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to more than 130 countries and its therapeutic products are sold in India, the USA and Europe. BE currently has 8 WHO-prequalified vaccines and 10 USFDA approved Generic Injectables in its portfolio. Recently, BE has received Emergency Use Listing (EUL) from the WHO for CORBEVAX®, the COVID-19 vaccine. Recently, DCGI has approved BE’S 14-Valent Pneumococcal Conjugate vaccine.

In recent years, BE has embarked on new initiatives for organizational expansion such as developing specialty injectable products for global markets as a means to manufacture APIs sustainably and developing novel vaccines for the global market.

Please follow us on Facebook, LinkedIn and Twitter

MEDIA CONTACTS

IVI

Aerie Em, Global Communications & Advocacy Manager
+82 2 881 1386 | aerie.em@ivi.int

Biological E. Limited

K. Vijay Amruth Raj
Email: Vijay.Kammari@biologicale.com
www.biologicale.com/news

END

[Attachments] See images for this press release:

IVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets 2

ELSE PRESS RELEASES FROM THIS DATE:

Rheumatic diseases associated with childbearing problems

2024-03-20

A new paper in Rheumatology, published by Oxford University Press, finds that rheumatic diseases can lead to reproductive problems, though some conditions have more detrimental effects than others. Immune-mediated diseases are a varied group of conditions, but each display an aberrant activity of the immune system. Some diseases, such as juvenile idiopathic arthritis and type 1 diabetes, occur mostly before patients reach their reproductive years, but others show up later in life. Scientists have investigated systemic lupus erythematosus for its impact on reproductive health; the condition increases the risk for some adverse pregnancy ...

Machine learning tools can predict emotion in voices in just over a second

2024-03-20

Words are important to express ourselves. What we don’t say, however, may be even more instrumental in conveying emotions. Humans can often tell how people around them feel through non-verbal cues embedded in our voice. Now, researchers in Germany wanted to find out if technical tools, too, can accurately predict emotional undertones in fragments of voice recordings. To do so, they compared three ML models’ accuracy to recognize diverse emotions in audio excepts. Their results were published in Frontiers in Psychology. “Here we show that machine learning can be used ...

Self-emergence of stational periodic arrangement of dual microdroplets through quasi one-dimensional confinement

2024-03-20

Polymer systems composed of multiple components can spontaneously induce emulsion or microdroplets by mechanical mixing, as an intermediate state of macroscopic phase separation. Unfortunately, the size of generated droplets is nonuniform and their spatial-arrangement is rather random. In addition, they tend to grow larger with time (coarsening). To prevent the change of the microdroplet size, researchers have currently attempted to rapidly lower the temperature, but these efforts can never improve the uniformity of the droplets. If uniformly arranged homogeneous droplets entrapping certain substrates such ...

Special efforts needed to allow 988 and 911 Systems to work in concert

2024-03-20

Getting the 988 and 911 emergency telephone systems to work in concert requires detailed planning and close cooperation, and such efforts may benefit from having one or two people at the local level who act as champions for interoperability, according to a new RAND report. In order to make sure callers are routed to the appropriate system, efforts need to involve representatives from both 988 and 911 call centers, law enforcement, mobile crisis teams, peer support specialists, behavioral health specialists, and people who have lived experience with crisis services, researchers say. Local champions can aid such efforts by establishing priorities, convening local stakeholders, brokering ...

Cryoablation highly effective for breast cancer patients with large tumors

2024-03-20

FAIRFAX, Va. (March 20, 2024)—A minimally invasive technique that uses ice to freeze and destroy small, cancerous tumors has now been proven effective for breast cancer patients with large tumors, providing a new treatment path for those who are not candidates for surgery, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City. “For patients who have larger tumors but can’t undergo surgery, this approach could be more effective than the current standard of care for patients who are not surgical candidates,” ...

More hysterectomies can be averted with earlier uterine artery embolization for postpartum hemorrhages

2024-03-20

FAIRFAX, Va. (March 20, 2024)—Early intervention with a minimally invasive treatment called uterine artery embolization (UAE) can help women avoid hysterectomy due to severe bleeding after childbirth, according to a new study being presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City. “These findings are important and may help more women avoid hysterectomy and other very serious complications of uncontrolled hemorrhage,” said lead author Younes Jahangiri, M.D., a third-year resident in the interventional and diagnostic radiology program at ...

New treatment option for prostate cancer shows successful outcomes

2024-03-20

FAIRFAX, Va. (March 20, 2024)—A minimally invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society of Interventional Radiology Annual Scientific Meeting in Salt Lake City. The traditional treatment options of radiation or surgery often come with a risk of side effects, including urinary incontinence and erectile dysfunction that cause significant morbidity and adverse lifestyle effects. Researchers said that some patients now have a durable alternative for whole-gland treatment with MRI-guided transurethral ultrasound ablation (TULSA) that does not preclude ...

ChatGPT is an effective tool for planning field work, school trips and even holidays

2024-03-20

Researchers exploring ways to utilise ChatGPT for work, say it could save organisations and individuals a lot of time and money when it comes to planning trips. A new study, published in Innovations in Education and Teaching International (IETI), has tested whether ChatGPT can be used to design University field studies. It found that the free-to-use AI model is an effective tool for not only planning educational trips around the world, but also could be used by other industries. The research, led by scientists from the University of Portsmouth and University of Plymouth, specifically ...

Metamaterials and AI converge, igniting innovative breakthroughs

2024-03-20

A research team, comprising Professor Junsuk Rho from the Department of Mechanical Engineering, the Department of Chemical Engineering, and the Department of Electrical Engineering, and PhD candidates Seokho Lee and Cherry Park from the Department of Mechanical Engineering at Pohang University of Science and Technology (POSTECH), has recently published a paper that highlights the next generation of research trends that combine metaphotonics research with artificial intelligence. The paper has been published in the international journal, Current Opinion in Solid State and Materials Science. Metalenses have sparked a revolution in optics, drastically ...

This could be forever: New design prolongs the lifespan of plasma torches

2024-03-20

Thanks for a new design contributed by a research team led by Prof. ZHAO Peng from Hefei Institutes of Physical Science (HFIPS) of Chinese Academy of Sciences (CAS), the operation time for plasma torch was extended from several days to several years. "We made the world's longest-lasting plasma torch," said Prof. ZHAO. Plasma torches, devices that generate thermal plasma, are pivotal in various industries due to their ability to efficiently produce high-temperature plasma. It can be applied in many fields including low-carbon metallurgy, powder spheroidization, carbon material preparation, and advanced ...

IVI starts technology transfer to Biological E. Limited to manufacture oral cholera vaccine for India and global markets

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: